4D Molecular Therapeutics, Inc. Total Liabilities and Equity
4D Molecular Therapeutics, Inc. (FDMT) had Total Liabilities and Equity of $492.62 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-13
- 2026-06-30: Liabilities and Equity $492.62M.
- 2026-03-31: Liabilities and Equity $512.90M.
- 2025-12-31: Liabilities and Equity $566.71M.
- 2025-09-30: Liabilities and Equity $423.98M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-06-30 | $492.62M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $512.90M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $566.71M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $423.98M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $473.64M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $515.73M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $560.38M 10-K · filed 2026-03-18 |
| 2024-09-30 | $604.03M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $620.12M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $629.88M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $339.89M 10-K · filed 2025-02-28 |
| 2023-09-30 | $361.61M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $352.50M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $244.02M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $261.85M 10-K · filed 2024-02-29 |
| 2022-09-30 | $280.16M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $302.94M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $324.93M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $353.49M 10-K · filed 2023-03-15 |
| 2021-09-30 | $240.62M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $254.93M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $270.11M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $288.33M 10-K · filed 2022-03-28 |
| 2019-12-31 | $58.23M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |